China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
Executive Summary
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.